Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,874.00
(
0.01%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
95.01
(
4.78%
)
Bitcoin
75,818.32
(
-0.10%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 208083

Wednesday, 03/22/2017 4:30:02 PM

Wednesday, March 22, 2017 4:30:02 PM

Post# of 257432
Quiz: In AZN’s phase-3 MYSTIC study in first-line NSCLC, why does the arm testing Durvalumab + Tremelimumab dose the former until disease progression but the latter for only four cycles?

ct.g listing for the trial:
https://www.clinicaltrials.gov/ct2/show/NCT02453282

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today